Citrate during Donor Plasmapheresis

被引:0
|
作者
Evers, J. [1 ]
Taborski, U. [1 ]
机构
[1] Octapharma Plasma & Plasmazentrum Aachen, Helleter Feldchen 9, D-52146 Aachen, Germany
关键词
apheresis; citrate; citrate infusion rate; citrate toxicity; plasmapheresis;
D O I
10.1055/s-0042-100560
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe the distribution of trisodium-citrate 4% anticoagulant between the product and the donors undergoing plasma donation. The paper is based upon data of 32 regular donors of plasma initially collected for a study published in 2010 [1]. These data were re-analysed to determine the amount of citrate received by the donor and the citrate infusion rate in mg/kg/min to the donor [2]. Donor plasmaphereses were performed with the automated Haemonetics r PCS2. 130 +/- 12 ml trisodium-citrate 4% was used for 760ml plasma. An average of 110 ml trisodiumcitrate 4% was in collected plasma and not given to the donor. From the difference of 20 ml trisodium- citrate 4% an average citrate infusion rate of 0.16 mg/kg/min was calculated. It was concluded that the total amount of citrate anion received by the donor is only 514 mg and that the average citrate infusion rate of 0.16mg/kg/min is very low [2].
引用
收藏
页码:23 / 25
页数:3
相关论文
共 50 条
  • [11] The effect of donor's characteristics on plasmapheresis products: insights for a personalised approach
    Merolle, Lucia
    Marraccini, Chiara
    Vurro, Filippo
    Parisi, Maura
    Di Bartolomeo, Erminia
    Bonvicini, Laura
    Broccoli, Serena
    Rossi, Paolo Giorgi
    Baricchi, Roberto
    Pertinhez, Thelma A.
    BLOOD TRANSFUSION, 2020, 18 (03) : 170 - 175
  • [12] Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis
    Ovali, E
    Ratip, S
    Özmenoglu, M
    Karti, SS
    Uçar, F
    Ukinç, K
    Yilmaz, M
    Kosucu, P
    TRANSFUSION AND APHERESIS SCIENCE, 2003, 28 (03) : 201 - 206
  • [13] Plasmapheresis in the ICU
    Hussein, Guleid
    Liu, Bolun
    Yadav, Sumeet K.
    Warsame, Mohamed
    Jamil, Ramsha
    Surani, Salim R.
    Khan, Syed A.
    MEDICINA-LITHUANIA, 2023, 59 (12):
  • [14] Management of Severe Hypertriglyceridemia with Plasmapheresis During Pregnancy
    Boyraz, Gokhan
    Yazicioglu, Aslihan
    Turgal, Mert
    Ozyuncu, Ozgur
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2015, 6 : 191 - 193
  • [15] Balancing Donor Health and Plasma Collection: A Systematic Review of the Impact of Plasmapheresis Frequency
    D'aes, Tine
    van den Hurk, Katja
    Schroyens, Natalie
    Mikkelsen, Susan
    Severijns, Pieter
    De Buck, Emmy
    O'Leary, Peter
    Tiberghien, Pierre
    Compernolle, Veerle
    Erikstrup, Christian
    Van Remoortel, Hans
    TRANSFUSION MEDICINE REVIEWS, 2024, 38 (04)
  • [16] Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis
    Pradhan, Madhura
    Raffaelli, Ryan M.
    Lind, Curt
    Meyers, Kevin E. C.
    Kaplan, Bernard S.
    Baluarte, Hobart J.
    Monos, Dimitri
    PEDIATRIC TRANSPLANTATION, 2008, 12 (06) : 711 - 716
  • [17] Citrate anticoagulation during CVVH in high risk bleeding patients
    Cubattoli, L.
    Teruzzi, M.
    Cormio, M.
    Lampati, L.
    Pesenti, A.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2007, 30 (03) : 244 - 252
  • [18] Serum complement activation of SLE patients during plasmapheresis
    Csipo, I
    Kavai, M
    Kiss, E
    Bedo, Z
    Csongor, J
    Szegedi, G
    Philbert, F
    Cohen, JHM
    AUTOIMMUNITY, 1997, 25 (03) : 139 - 146
  • [19] Complement activation as a cause of transient hypotension during plasmapheresis
    Shiga, Y
    Fujihara, K
    Onodera, H
    Nagata, T
    Itoyama, Y
    ARTIFICIAL ORGANS, 1998, 22 (12) : 1067 - 1069
  • [20] Theoretical Basis of Pathogenic Substance Removal During Plasmapheresis
    Hanafusa, Norio
    THERAPEUTIC APHERESIS AND DIALYSIS, 2011, 15 (05) : 421 - 430